Form 4: Co-Diagnostics Director Eugene Durenard Increases Direct Stock Ownership Through Routine RSU Vesting

Co-Diagnostics, Inc. Director Eugene Durenard acquired 48,334 shares of common stock through the scheduled vesting of restricted stock units, increasing his direct beneficial ownership to 211,667 shares.

Summary

• Eugene Durenard, a Director of Co-Diagnostics, Inc. (CODX), acquired 48,334 shares of common stock on May 23, 2025.
• This acquisition resulted from the vesting of previously awarded restricted stock units (RSUs) at a price of $0.00 per share.
• Following this transaction, Mr. Durenard directly beneficially owns 211,667 shares of Co-Diagnostics, Inc. common stock.
• Additionally, Mr. Durenard holds 103,333 restricted stock units, which represent the right to acquire 151,667 shares of common stock upon future vesting.
• The 48,334 shares vested on May 23, 2025, are part of multiple RSU awards granted between July 2022 and April 2024, which vest in six equal installments every six months.

Sentiment

Score: 5

Explanation: The document reports a routine insider transaction related to the vesting of restricted stock units, which is a standard form of equity compensation. It does not contain information that would significantly alter the sentiment towards the company's financial health or operational performance.

Positives

• Director Eugene Durenard increased his direct beneficial ownership in Co-Diagnostics, Inc. by 48,334 shares, aligning his interests further with shareholders.
• The acquisition of shares through RSU vesting at a $0.00 price indicates a non-cash compensation event, which is a common practice for executive and director compensation.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction. It only details the vesting schedule of previously awarded restricted stock units.

Industry Context

This Form 4 filing is a routine disclosure of insider stock ownership changes, specifically related to equity compensation. It does not provide information to analyze broader industry trends or competitive landscape for Co-Diagnostics, Inc.

Comparison to Industry Standards

• The document does not provide information that allows for a comparison of Co-Diagnostics, Inc.'s performance or operations against global industry benchmarks or specific comparable companies/projects.
• The vesting of restricted stock units as a form of executive compensation is a standard practice across many industries.

Related Party Transactions

• The vesting of restricted stock units awarded by Co-Diagnostics, Inc. to its Director, Eugene Durenard, constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The increase in direct beneficial ownership by a director may be viewed positively as it aligns management's interests with shareholders.
• Employees: The document details a standard form of equity compensation (RSUs), which is a common component of compensation packages for executives and directors.

Next Steps

• Future vesting installments of the remaining 103,333 restricted stock units will occur according to their respective six-month vesting schedules.

Key Dates

Keywords

Co-Diagnostics Inc., CODX, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Beneficial Ownership, Director Compensation, Equity Compensation, Eugene Durenard